Synapse - Thoracic Oncology

Results (3387)

Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study

Meeting Abstract

Brose, M. S.; Westphalen, C. B.; Kehl, K. L.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Meeting Abstract

Barlesi, F.; Felip, E.; Popat, S.; Solomon, B. J.; Wolf, J.; Li, B. T.; Wu, Y. L.; Kerr, K.; Akamatsu, H.; Camidge, D. R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial

Meeting Abstract

Li, B. T.; Clarke, J. M.; Felip, E.; Ruffinelli, J. C.; Garrido, P.; Zugazagoitia, J.; Goldberg, S. B.; Ramalingam, S. S.; Victoria, I.; Puri, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN

Meeting Abstract

Heymach, J.; Reck, M.; Mitsudomi, T.; Taube, J. M.; Spira, A. I.; Chaft, J. E.; Doherty, G. J.; Mann, H.; Fouad, T. M.; Harpole, D. H.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors

Meeting Abstract

Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade

Meeting Abstract

Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician's choice (TPC) in relapsed small cell lung cancer (SCLC)

Meeting Abstract

Owonikoko, T. K.; Byers, L. A.; Cheng, Y.; Hayashi, H.; Paz-Ares, L. G.; Perol, M.; Turner, J.; Qian, M.; Garcia, C. R.; Godard, J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study

Meeting Abstract

Langer, C. J.; Galot, R.; Prenen, H.; Hong, D. S.; Victoria, I.; Salgia, R.; Chenard-Poirier, M.; Furqan, M.; Chan, E.; Nolte-Hippenmeyer, J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors

Meeting Abstract

Schoenfeld, A. J.; Warner, A. B.; Chesney, J. A.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P. N.; Ramsingh, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HLA associations with immunotherapy related endocrine toxicity

Meeting Abstract

Quandt, Z.; Thorball, C.; Middha, P.; Johnson, D. B.; Bejan, C. A.; Yao, L.; Xu, Y.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save